Antineoplastic drug cytotoxicity in a human bladder cancer cell line: Implications for intravesical chemotherapy

SummaryThe clonogenic survival of MGH-U1 human bladder carcinoma cells treated with melphalan, cisplatin, mitomycin-C, adriamycin, vincristine and 5-fluorouracil was measured to determine the relative contribution of drug concentration and duration of exposure to cytotoxicity and to measure the relative cytotoxic effects of these agents used in intravesical chemotherapy. The survival curves were plotted as a function of log (CxT) and were fitted using a linear least squares analysis. The survival was the same for any given CxT whether this was determined by varying concentration or by varying the duration of exposure in the cases of melphalan, cisplatin, adriamycin, mitomycin-C and 5-fluorouracil. However, duration of exposure was more important than was drug concentration in the case of vincristine cytotoxicity. By utilizing the slope of the log (survival fraction) as a function of log (CxT), the relative cytotoxicity of each agent was determined. Mitomycin C, melphalan, adriamycin and cisplatin had comparable activity in this cell line, whereas vincristine and 5-fluorouracil demonstrated much lower cytotoxicity. We conclude that: 1) mitomycin-C, adriamycin and melphalan were the agents with the greatest cytotoxic efficacy; 2) determination of survival as a function of CxT can be used to separate the relative importance of concentration and of duration of exposure. 3) the cytotoxicity of 5/6 drugs studied was equal when the CxT was kept constant but concentration and exposure times were varied.

[1]  Y. Matsumura,et al.  Intravesical Adriamycin chemotherapy in bladder cancer , 1983, Cancer Chemotherapy and Pharmacology.

[2]  H. Green,et al.  Two types of ribosome in mouse-hamster hybrid cells. , 1971, Nature: New biology.

[3]  J. Richie,et al.  Intravesical doxorubicin for prophylaxis in the management of recurrent superficial bladder carcinoma. , 1984, The Journal of urology.

[4]  S. Loening,et al.  Superficial bladder cancer: progression and recurrence. , 1983, The Journal of urology.

[5]  W. Sadee,et al.  Regulation of RNA- and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells. , 1980, Cancer research.

[6]  D. Kufe,et al.  5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. , 1981, The Journal of biological chemistry.

[7]  J M Collins,et al.  Pharmacologic rationale for regional drug delivery. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Chabner Pharmacologic principles of cancer treatment , 1982 .

[9]  N. Walach,et al.  Intravesical chemotherapy of superficial bladder tumors in a controlled trial with cis‐platinum versus Cis‐platinum plus hyaluronidase , 1985, Journal of surgical oncology.

[10]  G. Prout,et al.  Establishment and characterization of four human bladder tumor cell lines and sublines with different degrees of malignancy. , 1985, Cancer research.

[11]  W. Frable,et al.  The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder. , 1981, The Journal of urology.

[12]  B. Hill,et al.  Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line , 2004, Urological Research.

[13]  G. Prout,et al.  Cell cycles in two cell lines of human bladder carcinoma. , 1977, The Tohoku journal of experimental medicine.

[14]  R. Heimer,et al.  Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. , 1979, Science.

[15]  D. Tolley,et al.  Intravesical mitomycin C therapy for superficial bladder cancer. Report of a multicentre phase II study. , 1985, British journal of urology.

[16]  F. Torti,et al.  The biology and treatment of superficial bladder cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.